Cardiopulmary Oxygenator Market Scope And Analysis

Report Code : TIPRE00029843
Category : Medical Device

Status : Published
No. of Pages : 236

Buy Now

Cardiopulmonary Oxygenator Market Scope and Key Players Analysis by 2028

Buy Now

Cardiopulmonary Oxygenator Market Report Scope

Report Attribute	Details
Market size in 2022	US$ 716.21 Million
Market Size by 2028	US$ 904.15 Million
Global CAGR (2022 - 2028)	4.0%
Historical Data	2020-2021
Forecast period	2023-2028
Segments Covered	By Product Bubble Oxygenator and Membrane Oxygenator By Application Cardiac and Respiratory By Type Disposable Cardiopulmonary Oxygenator and Reusable Cardiopulmonary Oxygenator By Age Group Adults Pediatric Neonates
Regions and Countries Covered	North America US Canada Mexico Europe UK Germany France Russia Italy Rest of Europe Asia-Pacific China India Japan Australia Rest of Asia-Pacific South and Central America Brazil Argentina Rest of South and Central America Middle East and Africa South Africa Saudi Arabia UAE Rest of Middle East and Africa
Market leaders and key company profiles	Getinge AB LivaNova Plc Medtronic Plc Terumo Corp Eurosets SRL Nipro Medical Corp Fresenius Medical Care AG Co KGaA MicroPort Scientific Corp Braile Biom dica Industry Commerce and Representations Ltd

The major market players operating in the cardiopulmonary oxygenators market are Getinge AB, LivaNova Plc, Medtronic Plc, Terumo Corp, Eurosets SRL, Nipro Medical Corp, Fresenius Medical Care AG & Co. KGaA, MicroPort Scientific Corp, Braile Biomédica Industry, Commerce and Representations Ltd, and Chalice Medical Ltd.

Cardiopulmonary oxygenator market players mainly focus on product approval and company expansion to create customer value.

In Nov 2022, LivaNova PLC announced it received 510(k) clearance for extracorporeal membrane oxygenation (ECMO) from the US Food and Drug Administration (FDA) for LifeSPARC, the Company’s next-generation Advanced Circulatory Support (ACS) pump and controller system.
In Feb 2022, Fresenius Medical Care announced that the US Food and Drug Administration (FDA) had cleared Novalung, a heart and lung support system for the treatment of acute respiratory or cardiopulmonary failure. Novalung is the first extracorporeal membrane oxygenation (ECMO) system to be cleared for more than six hours of use as extracorporeal life support.
In Dec 2020, Nipro Medical Corp announced that Nipro Australia PTY LTD, its consolidated subsidiary, had established a sales office in Melbourne, Victoria, Australia.